Longitudinal Measurements of Blood Biomarkers in Patients with Crohn's Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure
Few studies have incorporated longitudinal assessments or used combinations of blood biomarkers as predictors of loss of response to biologic therapy for patients with Crohn's disease (CD) or ulcerative colitis (UC). This is a population-based cohort study comprising Danish patients with CD or...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2024-02, Vol.13 (4), p.926 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 926 |
| container_title | Journal of clinical medicine |
| container_volume | 13 |
| creator | Gradel, Kim Oren Nørgård, Bente Mertz Friedman, Sonia Kjeldsen, Jens Larsen, Michael Due |
| description | Few studies have incorporated longitudinal assessments or used combinations of blood biomarkers as predictors of loss of response to biologic therapy for patients with Crohn's disease (CD) or ulcerative colitis (UC).
This is a population-based cohort study comprising Danish patients with CD or UC from 2008 to 2018. We used logistic regression to analyze whether levels and changes in levels of C-reactive protein (CRP), serum albumin, and hemoglobin, routinely measured during a 14-week infliximab induction period, predicted a change to another biologic medication or cessation of biologic therapy.
During the induction period, 2883 (1626 CD, 1257 UC) patients had 12,730, 12,040, and 13,538 specimens with CRP, serum albumin, and hemoglobin, respectively. In all, 284 patients (9.9%) switched to another biologic medication, and 139 (4.8%) ceased biologic therapy in the follow-up period. Only the most recent CRP and hemoglobin levels predicted the efficacy of infliximab treatment at approximately 14 weeks, a time point when the clinician often determines whether to continue treatment.
Measurement of blood biomarkers prior to the clinical assessment does not predict the effectiveness of infliximab. |
| doi_str_mv | 10.3390/jcm13040926 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2932434454</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A784041197</galeid><sourcerecordid>A784041197</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-b92a1f6ec6f9abded1c82c9a3b22f17913e56995dd4d319c1bf91a7fdf1797273</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEolXpiTuyxAGkaou_Nom5tVsKKy1qDy3XyLHHXS-OXWwH6B_kd-HsFigI-2Br5nlnXo2mqp4TfMyYwG82aiAMcyxo_ajap7hpZpi17PGD_151mNIGl9O2nJLmabVXoqKlHO9XP1bB39g8auulQx9BpjHCAD4nFAw6dSFodGrDIONniAlZjy5lttv8N5vXaBHD2r9K6MymogUUIrp2CmKBvgJaBGezTegqgsygd5KlN85-t4Ps36IL7-5QXgNalXzK6JN0I2zbTMGl16PKNpSmEG1xchlBW5V39SaX6FxaVxw_q54Y6RIc3r8H1fX5u6vFh9nq4v1ycbKaKdaIPOsFlcTUoGojZK9BE9VSJSTrKTWkEYTBvBZirjXXjAhFeiOIbIyekg1t2EH1elf3NoYvxWnuBpsUOCc9hDF1VDDKGedzXtCX_6CbMMYy5S2FRU0FIX-oG-mgs96EHKWainYnTcsxJ0RMbY__Q5WrYbAqeDC2xP8SHO0EKoaUIpjuNpaJx7uO4G5anO7B4hT6xb3VsR9A_2Z_rQn7CQogv68</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2930962911</pqid></control><display><type>article</type><title>Longitudinal Measurements of Blood Biomarkers in Patients with Crohn's Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Gradel, Kim Oren ; Nørgård, Bente Mertz ; Friedman, Sonia ; Kjeldsen, Jens ; Larsen, Michael Due</creator><creatorcontrib>Gradel, Kim Oren ; Nørgård, Bente Mertz ; Friedman, Sonia ; Kjeldsen, Jens ; Larsen, Michael Due</creatorcontrib><description>Few studies have incorporated longitudinal assessments or used combinations of blood biomarkers as predictors of loss of response to biologic therapy for patients with Crohn's disease (CD) or ulcerative colitis (UC).
This is a population-based cohort study comprising Danish patients with CD or UC from 2008 to 2018. We used logistic regression to analyze whether levels and changes in levels of C-reactive protein (CRP), serum albumin, and hemoglobin, routinely measured during a 14-week infliximab induction period, predicted a change to another biologic medication or cessation of biologic therapy.
During the induction period, 2883 (1626 CD, 1257 UC) patients had 12,730, 12,040, and 13,538 specimens with CRP, serum albumin, and hemoglobin, respectively. In all, 284 patients (9.9%) switched to another biologic medication, and 139 (4.8%) ceased biologic therapy in the follow-up period. Only the most recent CRP and hemoglobin levels predicted the efficacy of infliximab treatment at approximately 14 weeks, a time point when the clinician often determines whether to continue treatment.
Measurement of blood biomarkers prior to the clinical assessment does not predict the effectiveness of infliximab.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm13040926</identifier><identifier>PMID: 38398240</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Biological markers ; Biomarkers ; Crohn's disease ; Diagnosis ; Dosage and administration ; Drug therapy ; Evaluation ; Hemoglobin ; Induction therapy ; Inflammatory bowel disease ; Infliximab ; Monoclonal antibodies ; Patient outcomes ; Patients ; Population-based studies ; Prognosis ; Regression analysis ; Tumor necrosis factor-TNF ; Ulcerative colitis</subject><ispartof>Journal of clinical medicine, 2024-02, Vol.13 (4), p.926</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c379t-b92a1f6ec6f9abded1c82c9a3b22f17913e56995dd4d319c1bf91a7fdf1797273</cites><orcidid>0000-0001-8148-6572 ; 0000-0002-9514-3033 ; 0000-0002-2720-4404 ; 0000-0002-5611-2031 ; 0000-0002-0623-2481</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38398240$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gradel, Kim Oren</creatorcontrib><creatorcontrib>Nørgård, Bente Mertz</creatorcontrib><creatorcontrib>Friedman, Sonia</creatorcontrib><creatorcontrib>Kjeldsen, Jens</creatorcontrib><creatorcontrib>Larsen, Michael Due</creatorcontrib><title>Longitudinal Measurements of Blood Biomarkers in Patients with Crohn's Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>Few studies have incorporated longitudinal assessments or used combinations of blood biomarkers as predictors of loss of response to biologic therapy for patients with Crohn's disease (CD) or ulcerative colitis (UC).
This is a population-based cohort study comprising Danish patients with CD or UC from 2008 to 2018. We used logistic regression to analyze whether levels and changes in levels of C-reactive protein (CRP), serum albumin, and hemoglobin, routinely measured during a 14-week infliximab induction period, predicted a change to another biologic medication or cessation of biologic therapy.
During the induction period, 2883 (1626 CD, 1257 UC) patients had 12,730, 12,040, and 13,538 specimens with CRP, serum albumin, and hemoglobin, respectively. In all, 284 patients (9.9%) switched to another biologic medication, and 139 (4.8%) ceased biologic therapy in the follow-up period. Only the most recent CRP and hemoglobin levels predicted the efficacy of infliximab treatment at approximately 14 weeks, a time point when the clinician often determines whether to continue treatment.
Measurement of blood biomarkers prior to the clinical assessment does not predict the effectiveness of infliximab.</description><subject>Biological markers</subject><subject>Biomarkers</subject><subject>Crohn's disease</subject><subject>Diagnosis</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Evaluation</subject><subject>Hemoglobin</subject><subject>Induction therapy</subject><subject>Inflammatory bowel disease</subject><subject>Infliximab</subject><subject>Monoclonal antibodies</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Population-based studies</subject><subject>Prognosis</subject><subject>Regression analysis</subject><subject>Tumor necrosis factor-TNF</subject><subject>Ulcerative colitis</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptkk1v1DAQhiMEolXpiTuyxAGkaou_Nom5tVsKKy1qDy3XyLHHXS-OXWwH6B_kd-HsFigI-2Br5nlnXo2mqp4TfMyYwG82aiAMcyxo_ajap7hpZpi17PGD_151mNIGl9O2nJLmabVXoqKlHO9XP1bB39g8auulQx9BpjHCAD4nFAw6dSFodGrDIONniAlZjy5lttv8N5vXaBHD2r9K6MymogUUIrp2CmKBvgJaBGezTegqgsygd5KlN85-t4Ps36IL7-5QXgNalXzK6JN0I2zbTMGl16PKNpSmEG1xchlBW5V39SaX6FxaVxw_q54Y6RIc3r8H1fX5u6vFh9nq4v1ycbKaKdaIPOsFlcTUoGojZK9BE9VSJSTrKTWkEYTBvBZirjXXjAhFeiOIbIyekg1t2EH1elf3NoYvxWnuBpsUOCc9hDF1VDDKGedzXtCX_6CbMMYy5S2FRU0FIX-oG-mgs96EHKWainYnTcsxJ0RMbY__Q5WrYbAqeDC2xP8SHO0EKoaUIpjuNpaJx7uO4G5anO7B4hT6xb3VsR9A_2Z_rQn7CQogv68</recordid><startdate>20240201</startdate><enddate>20240201</enddate><creator>Gradel, Kim Oren</creator><creator>Nørgård, Bente Mertz</creator><creator>Friedman, Sonia</creator><creator>Kjeldsen, Jens</creator><creator>Larsen, Michael Due</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8148-6572</orcidid><orcidid>https://orcid.org/0000-0002-9514-3033</orcidid><orcidid>https://orcid.org/0000-0002-2720-4404</orcidid><orcidid>https://orcid.org/0000-0002-5611-2031</orcidid><orcidid>https://orcid.org/0000-0002-0623-2481</orcidid></search><sort><creationdate>20240201</creationdate><title>Longitudinal Measurements of Blood Biomarkers in Patients with Crohn's Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure</title><author>Gradel, Kim Oren ; Nørgård, Bente Mertz ; Friedman, Sonia ; Kjeldsen, Jens ; Larsen, Michael Due</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-b92a1f6ec6f9abded1c82c9a3b22f17913e56995dd4d319c1bf91a7fdf1797273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biological markers</topic><topic>Biomarkers</topic><topic>Crohn's disease</topic><topic>Diagnosis</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Evaluation</topic><topic>Hemoglobin</topic><topic>Induction therapy</topic><topic>Inflammatory bowel disease</topic><topic>Infliximab</topic><topic>Monoclonal antibodies</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Population-based studies</topic><topic>Prognosis</topic><topic>Regression analysis</topic><topic>Tumor necrosis factor-TNF</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gradel, Kim Oren</creatorcontrib><creatorcontrib>Nørgård, Bente Mertz</creatorcontrib><creatorcontrib>Friedman, Sonia</creatorcontrib><creatorcontrib>Kjeldsen, Jens</creatorcontrib><creatorcontrib>Larsen, Michael Due</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gradel, Kim Oren</au><au>Nørgård, Bente Mertz</au><au>Friedman, Sonia</au><au>Kjeldsen, Jens</au><au>Larsen, Michael Due</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Longitudinal Measurements of Blood Biomarkers in Patients with Crohn's Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2024-02-01</date><risdate>2024</risdate><volume>13</volume><issue>4</issue><spage>926</spage><pages>926-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Few studies have incorporated longitudinal assessments or used combinations of blood biomarkers as predictors of loss of response to biologic therapy for patients with Crohn's disease (CD) or ulcerative colitis (UC).
This is a population-based cohort study comprising Danish patients with CD or UC from 2008 to 2018. We used logistic regression to analyze whether levels and changes in levels of C-reactive protein (CRP), serum albumin, and hemoglobin, routinely measured during a 14-week infliximab induction period, predicted a change to another biologic medication or cessation of biologic therapy.
During the induction period, 2883 (1626 CD, 1257 UC) patients had 12,730, 12,040, and 13,538 specimens with CRP, serum albumin, and hemoglobin, respectively. In all, 284 patients (9.9%) switched to another biologic medication, and 139 (4.8%) ceased biologic therapy in the follow-up period. Only the most recent CRP and hemoglobin levels predicted the efficacy of infliximab treatment at approximately 14 weeks, a time point when the clinician often determines whether to continue treatment.
Measurement of blood biomarkers prior to the clinical assessment does not predict the effectiveness of infliximab.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38398240</pmid><doi>10.3390/jcm13040926</doi><orcidid>https://orcid.org/0000-0001-8148-6572</orcidid><orcidid>https://orcid.org/0000-0002-9514-3033</orcidid><orcidid>https://orcid.org/0000-0002-2720-4404</orcidid><orcidid>https://orcid.org/0000-0002-5611-2031</orcidid><orcidid>https://orcid.org/0000-0002-0623-2481</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2024-02, Vol.13 (4), p.926 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2932434454 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Biological markers Biomarkers Crohn's disease Diagnosis Dosage and administration Drug therapy Evaluation Hemoglobin Induction therapy Inflammatory bowel disease Infliximab Monoclonal antibodies Patient outcomes Patients Population-based studies Prognosis Regression analysis Tumor necrosis factor-TNF Ulcerative colitis |
| title | Longitudinal Measurements of Blood Biomarkers in Patients with Crohn's Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A34%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Longitudinal%20Measurements%20of%20Blood%20Biomarkers%20in%20Patients%20with%20Crohn's%20Disease%20or%20Ulcerative%20Colitis%20Treated%20with%20Infliximab:%20Only%20the%20Latest%20Values%20in%20the%20Induction%20Period%20Predict%20Treatment%20Failure&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Gradel,%20Kim%20Oren&rft.date=2024-02-01&rft.volume=13&rft.issue=4&rft.spage=926&rft.pages=926-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm13040926&rft_dat=%3Cgale_proqu%3EA784041197%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2930962911&rft_id=info:pmid/38398240&rft_galeid=A784041197&rfr_iscdi=true |